In Vitro Efficacy of Imipenem/Relebactam Against Imipenem Resistant Gram-Negative Strains Isolated from a Tertiary Care Hospital
DOI:
https://doi.org/10.51253/pafmj.v74i1.9901Keywords:
Carbapenems, Imipenem, Anti-bacterial agents, Drug resistance, Bacterial drug resistance, Multiple drug resistanceAbstract
Objective: To determine in vitro efficacy of Imipenem/Relebactam against multi-drug resistant strains.
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Microbiology, Fauji Foundation Hospital (FFH) Rawalpindi, Pakistan from Jul to Dec 2022.
Methodology: All specimens from indoor and outdoor patients with infection due to Gram-negative organisms showing
resistance to Imipenem disc (10μg) were included. Cultures were inoculated on Blood and MacConkey’s agar. Imipenemresistant Gram-negative species identification was made by Gram stain, Oxidase test and commercially available identification strips Analytical profile index 10S (API-10S) (from bioMerieux, Inc.).Imipenem-resistant species were identified, showing a zone diameter of less than 23mm against10µg Imipenem disc for Enterobacterale and Non-Enterobacterales, and for Pseudomonas species, zone size is ≤19mm. These resistant organisms were tested for sensitivity against
Imipenem/Relebactam by E-strip (MTSTM –MIC Test Strip) (Liofilchem, Inc., Waltham, MA).
Results: Out of 160 Carbapenem-resistant Enterobacterale and Non-Enterobacterales specimens, only 14 isolates (including 02 Pseudomonas spp.) showed susceptibility to Imipenem/Relebactam combination of drug. US-FDA Imipenem/Relebactam
susceptibility interpretive criteria (STIC) was used.
Conclusion: In our setup, only 8.75% isolates showed sensitivity to this newer drug combination Imipenem/Relebactum. This highlights the importance of evaluating newer drugs in our population before using them empirically.
Downloads
Metrics
References
Vivas R, Barbosa AAT, Dolabela SS, Jain S. Multidrug-Resistant
Bacteria and Alternative Methods to Control Them: An
Overview. Microb Drug Resist 2019; 25(6): 890-908.
https://doi.org/10.1089/mdr.2018.0319.
Lozano C, Torres C. Actualización en la resistencia antibiótica en
Gram positivos [Update on antibiotic resistance in Gram-positive
bacteria]. Enferm Infecc Microbiol Clin 2017; 35 Suppl 1:2-8.
https://doi.org/10.1016/S0213-005X(17)30028-9.
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D,
David-Wang A, Boucher HW, et al. A Randomized, Doubleblind, Multicenter Trial Comparing Efficacy and Safety of
Imipenem/Cilastatin/Relebactam Versus
Piperacillin/Tazobactam in Adults With Hospital-acquired or
Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2
Study). Clin Infect Dis 2021; 73(11): e4539-e4548.
https://doi.org/10.1093/cid/ciaa803.
Campanella TA, Gallagher JC. A Clinical Review and Critical
Evaluation of Imipenem-Relebactam: Evidence to Date. Infect
Drug Resist 2020; 13: 4297-4308.
https://doi.org/10.2147/IDR.S224228.
Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore DM.
Activity of imipenem/relebactam against Pseudomonas
aeruginosa producing ESBLs and carbapenemases. J Antimicrob
Chemother 2021; 76(2): 434-442.
https://doi.org/10.1093/jac/dkaa456.
Cruz-López F, Martínez-Meléndez A, Morfin-Otero R,
Rodriguez-Noriega E, Maldonado-Garza HJ, Garza-González E.
Efficacy and In Vitro Activity of Novel Antibiotics for Infections
With Carbapenem-Resistant Gram-Negative Pathogens. Front
Cell Infect Microbiol 2022; 12: 884365.
https://doi.org/10.3389/fcimb.2022.884365.
Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C,
Landman D, et al. Activity of Imipenem with Relebactam against
Gram-Negative Pathogens from New York City. Antimicrob
Agents Chemother 2015; 59(8): 5029-31.
https://doi.org/ 10.1128/AAC.00830-15.
Yang T-Y, Hsieh Y-J, Kao L-T, Liu GH, Lian S-H, Wang L-C, et al.
Activities of imipenem-relebactam combination against
carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. J
Microbiol Immunol Infect 2022; 55(1): 86-94.
https://doi.org/ 10.1016/j.jmii.2021.02.001.
Heo YA. Imipenem/Cilastatin/Relebactam: A Review in GramNegative Bacterial Infections. Drugs 2021; 81(3): 377-388.
https://doi.org/10.1007/s40265-021-01471-8.
Kurihara D, Matsumoto S, Kishi N, Ishii Y, Mori M. In Vitro
Antibacterial Activity of Imipenem/Relebactam against Clinical
Isolates in Japan. Microbiol Spectr 2022; 10(2): e0223521.
https://doi.org/10.1128/spectrum.02235-21.
Gebre AB, Begashaw TA, Ormago MD. Bacterial profile and
drug susceptibility among adult patients with community
acquired lower respiratory tract infection at tertiary hospital,
Southern Ethiopia. BMC Infect Dis 2021; 21(1):
https://doi.org/10.1186/s12879-021-06151-2.
Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari
ND, et al. In vitro activity of imipenem-relebactam against
resistant phenotypes of Enterobacteriaceae and Pseudomonas
aeruginosa isolated from intraabdominal and urinary tract
infection samples - SMART Surveillance Europe 2015-2017. J
Med Microbiol 2020; 69(2): 207-217.
https://doi.org/10.1099/jmm.0.001142.
Mansour H, Ouweini AEL, Chahine EB, Karaoui LR.
Imipenem/cilastatin/relebactam: A new carbapenem βlactamase inhibitor combination. Am J Health Syst Pharm 2021;
(8): 674-683. https://doi.org/10.1093/ajhp/zxab012.
Dhingra S, Rahman NAA, Peile E, Rahman M, Sartelli M, Hassali
MA, et al. Microbial Resistance Movements: An Overview of
Global Public Health Threats Posed by Antimicrobial Resistance,
and How Best to Counter. Front Public Health 2020; 8: 535668.
https://doi.org/10.3389/fpubh.2020.535668.
Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR,
Becka SA, et al. Relebactam Is a Potent Inhibitor of the KPC-2 βLactamase and Restores Imipenem Susceptibility in KPCProducing Enterobacteriaceae. Antimicrob Agents Chemother
; 62(6): e00174-18. https://doi.org/10.1128/AAC.00174-18.
O'Donnell JN, Lodise TP. New Perspectives on Antimicrobial
Agents: Imipenem-Relebactam. Antimicrob Agents Chemother
; 66(7): e0025622. https://doi.org/10.1128/aac.00256-22.
Downloads
Published
How to Cite
Issue
Section
